(5-isopropylpyridin-3-yl)methanol | 1383568-53-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (5-isopropylpyridin-3-yl)methanol
• 英文别名: (5-propan-2-ylpyridin-3-yl)methanol
• CAS: 1383568-53-3
• 化学式: C₉H₁₃NO
• 分子量: 151.208
• InChiKey: FLRGCAQFNKENPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-chloro-5-isopropylnicotinaldehyde 在 氢气 、 sodium acetate 、 palladium dichloride 作用下， 以 甲醇 为溶剂， 35.0 ℃ 、101.33 kPa 条件下， 反应 2.0h， 以85%的产率得到(5-isopropylpyridin-3-yl)methanol
  参考文献：
  名称：

  Simultaneous dehalogenation and hydrogenation reduction of halogen-heteroaromatic aldehydes

  摘要：

  Treatment of halogen-heteroaromatic aldehydes with catalytic amount of PdCl2 under atmosphere pressure of hydrogen in base medium (sodium acetate) leads to the corresponding dehalogenated primary alcohols. The reaction system was especially effective for the heteroaromatic compounds bearing aldehyde groups and halides (bromo- or chloro-functions). Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2012.05.054

文献信息

• Process for producing heterocyclic aldehyde
  申请人：Shiomi Yasuhiro

  公开号：US20050124807A1

  公开（公告）日：2005-06-09

  The present invention provides a process for preparing a heterocyclic aldehyde by oxidizing a heterocyclic alcohol with high selectivity and high yield. Specifically, the heterocyclic aldehyde is prepared by reacting a heterocyclic compound having at least one hydroxymethyl group bonded to a carbon atom of a heterocyclic ring with a hypohalogenous acid salt in the presence of a base to oxidize the hydroxymethyl group, wherein reaction is conducted in the co-presence of a 2,2,6,6-tetramethylpiperidine-1-oxyl derivative having at least two 2,2,6,6-tetramethylpiperidine-1-oxyl-4-yl groups.

  本发明提供了一种通过氧化具有高选择性和高产率的杂环醇来制备杂环醛的方法。具体来说，通过将至少有一个羟甲基基团与杂环环的碳原子键合的杂环化合物与次氯酸盐在碱的存在下反应，氧化羟甲基基团来制备杂环醛，其中反应在共存至少具有两个2,2,6,6-四甲基哌啶-1-氧基-4-基团的2,2,6,6-四甲基哌啶-1-氧基-4-基团的2,2,6,6-四甲基哌啶-1-氧基-4-基团的共存下进行。
• Aryl substituted imidazonaphthyridines
  申请人：Niwas Shri

  公开号：US20070219228A1

  公开（公告）日：2007-09-20

  Imidazonaphthyridine ring systems substituted with an aryl substituent, pharmaceutical compositions containing the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

  本发明公开了以芳基取代的咪唑萘啉环系统化合物、含有该化合物的制药组合物，以及将这些化合物用作免疫调节剂的方法，用于在动物体内诱导细胞因子的生物合成，并用于治疗包括病毒性和肿瘤性疾病在内的疾病。
• NEW CHEMICAL COMPOUNDS
  申请人：Steurer Steffen

  公开号：US20110312939A1

  公开（公告）日：2011-12-22

  The present invention relates to new compounds of general formula (I), wherein the groups R 1 to R 3 , X 1 , X 2 , X 3 and L 1 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof in such a treatment.

  本发明涉及一般式（I）的新化合物，其中R1至R3、X1、X2、X3和L1的基团如权利要求书所定义，适用于治疗以过度或异常细胞增殖为特征的疾病，并且本发明还涉及这些化合物在此类治疗中的使用。
• ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20140038936A1

  公开（公告）日：2014-02-06

  The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

  本发明涉及用作PI3K抑制剂的化合物，特别是PI3Kγ的抑制剂。本发明还提供了包含该化合物的药学上可接受的组合物，并提供了使用该组合物治疗各种疾病、病况或障碍的方法。
• Isoindolinone inhibitors of phosphatidylinositol 3-kinase
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US10183933B2

  公开（公告）日：2019-01-22

  The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

  本发明涉及可用作 PI3K（尤其是 PI3Kγ）抑制剂的化合物。本发明还提供了包含所述化合物的药学上可接受的组合物，以及使用该组合物治疗各种疾病、病症或失调的方法。